dexborneol
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Nov 30, 2023 (NCT06138834)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](O)C2- Mol. weight
- 154.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL486208 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07040085 | Phase 3 | Aug 5, 2025 | Capital Medical University, NeuroDawn Pharmaceutical Co., Ltd. |
| NCT06176781 | Phase 3 | Dec 28, 2023 | Simcere Pharmaceutical Co., Ltd |
| NCT06138834 | Phase 2 | Nov 30, 2023 | Capital Medical University, NeuroDawn Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 2 | 2 | 2 | 2023 |
| NeuroDawn Pharmaceutical Co., Ltd. | For profit | 2 | 0 | 2 | 2023 |
| Simcere Pharmaceutical Co., Ltd | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1